Ph.D., University of Washington, Biostatistics, 1989.
M.S., State University of New York at Binghamton, Mathematics, 1983.
My interests and areas of expertise are:
Design, analysis, and conduct of randomized trials
Chronic disease prevention research
Ovarian cancer, including biomarkers, screening, and risk
American Statistical Association
International Biometric Society
Society for Controlled Clinical Trials
1995-2002, Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
1989-1995, Assistant Member, Fred Hutchinson Cancer Research Center, Biostatistics, Public Health Sciences
1989-1997, Affiliate Assistant Professor, University of Washington, Public Health, Biostatistics
Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.. Journal of the National Cancer Institute. 108(6). 2016.
Embedding Clinical Interventions into Observational Studies.. Contemporary clinical trials. 46:100–105.. 2016.
Circulating estrogens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2016.
Narrowing of racial disparities in breast cancer incidence: insights from menopausal hormone therapy study findings.. Journal of the National Cancer Institute. 108(4). 2016.
A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women.. Journal of the National Cancer Institute. 107(10). 2015.
Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply.. JAMA oncology. 1(8):1171.. 2015.
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.. Gynecologic oncology. 139(2):253-260.. 2015.
Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative Study.. Journal of women's health (2002). 24(3):218-27.. 2015.
Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(7):917-24.. 2015.
Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.. Journal of the National Cancer Institute. 108(2). 2015.
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.. Obstetrics and gynecology. 126(2):413-22.. 2015.
Oral bisphosphonate use and risk of postmenopausal endometrial cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(10):1186-90.. 2015.
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.. Journal of the National Cancer Institute. 107(4). 2015.
Menopausal hormone therapy and breast cancer mortality: clinical implications.. Therapeutic advances in drug safety. 6(2):45-56.. 2015.
Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 23(11):2393-403.. 2014.
Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study.. Annals of internal medicine. 160(9):594-602.. 2014.
Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage.. Cancer causes & control : CCC.. 2014.
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2014.
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.. Breast cancer research : BCR. 16(2):R30.. 2014.
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.. European journal of cancer (Oxford, England : 1990).. 2014.
Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: Results from the Women's Health Initiative.. Gynecologic oncology. 133(1):4-10.. 2014.